|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 3195 |
FusionGeneSummary for ATG5_EPHA7 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ATG5_EPHA7 | Fusion gene ID: 3195 | Hgene | Tgene | Gene symbol | ATG5 | EPHA7 | Gene ID | 9474 | 2045 |
| Gene name | autophagy related 5 | EPH receptor A7 | |
| Synonyms | APG5|APG5-LIKE|APG5L|ASP|SCAR25|hAPG5 | EHK-3|EHK3|EK11|HEK11 | |
| Cytomap | 6q21 | 6q16.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | autophagy protein 5APG5 autophagy 5-likeATG5 autophagy related 5 homologapoptosis-specific protein | ephrin type-A receptor 7EPH homology kinase 3EPH-like kinase 11Eph homology kinase-3receptor protein-tyrosine kinase HEK11tyrosine-protein kinase receptor EHK-3 | |
| Modification date | 20180527 | 20180523 | |
| UniProtAcc | Q9H1Y0 | Q15375 | |
| Ensembl transtripts involved in fusion gene | ENST00000343245, ENST00000369070, ENST00000369076, ENST00000360666, ENST00000475645, | ENST00000369303, ENST00000369297, | |
| Fusion gene scores | * DoF score | 16 X 8 X 9=1152 | 1 X 1 X 1=1 |
| # samples | 16 | 1 | |
| ** MAII score | log2(16/1152*10)=-2.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(1/1*10)=3.32192809488736 | |
| Context | PubMed: ATG5 [Title/Abstract] AND EPHA7 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | EPHA7 | GO:0048013 | ephrin receptor signaling pathway | 17726105 |
| Tgene | EPHA7 | GO:0050730 | regulation of peptidyl-tyrosine phosphorylation | 17726105 |
| Tgene | EPHA7 | GO:0070372 | regulation of ERK1 and ERK2 cascade | 17726105 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | RV | LUSC | TCGA-98-A53B-01A | ATG5 | chr6 | 106756239 | - | EPHA7 | chr6 | 93982140 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000343245 | ENST00000369303 | ATG5 | chr6 | 106756239 | - | EPHA7 | chr6 | 93982140 | - |
| 5CDS-intron | ENST00000343245 | ENST00000369297 | ATG5 | chr6 | 106756239 | - | EPHA7 | chr6 | 93982140 | - |
| intron-3CDS | ENST00000369070 | ENST00000369303 | ATG5 | chr6 | 106756239 | - | EPHA7 | chr6 | 93982140 | - |
| intron-intron | ENST00000369070 | ENST00000369297 | ATG5 | chr6 | 106756239 | - | EPHA7 | chr6 | 93982140 | - |
| In-frame | ENST00000369076 | ENST00000369303 | ATG5 | chr6 | 106756239 | - | EPHA7 | chr6 | 93982140 | - |
| 5CDS-intron | ENST00000369076 | ENST00000369297 | ATG5 | chr6 | 106756239 | - | EPHA7 | chr6 | 93982140 | - |
| intron-3CDS | ENST00000360666 | ENST00000369303 | ATG5 | chr6 | 106756239 | - | EPHA7 | chr6 | 93982140 | - |
| intron-intron | ENST00000360666 | ENST00000369297 | ATG5 | chr6 | 106756239 | - | EPHA7 | chr6 | 93982140 | - |
| intron-3CDS | ENST00000475645 | ENST00000369303 | ATG5 | chr6 | 106756239 | - | EPHA7 | chr6 | 93982140 | - |
| intron-intron | ENST00000475645 | ENST00000369297 | ATG5 | chr6 | 106756239 | - | EPHA7 | chr6 | 93982140 | - |
Top |
FusionProtFeatures for ATG5_EPHA7 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ATG5 | EPHA7 |
| Involved in autophagic vesicle formation. Conjugationwith ATG12, through a ubiquitin-like conjugating system involvingATG7 as an E1-like activating enzyme and ATG10 as an E2-likeconjugating enzyme, is essential for its function. The ATG12-ATG5conjugate acts as an E3-like enzyme which is required forlipidation of ATG8 family proteins and their association to thevesicle membranes. Involved in mitochondrial quality control afteroxidative damage, and in subsequent cellular longevity. Plays acritical role in multiple aspects of lymphocyte development and isessential for both B and T lymphocyte survival and proliferation.Required for optimal processing and presentation of antigens forMHC II. Involved in the maintenance of axon morphology andmembrane structures, as well as in normal adipocytedifferentiation. Promotes primary ciliogenesis through removal ofOFD1 from centriolar satellites and degradation of IFT20 via theautophagic pathway. {ECO:0000250|UniProtKB:Q99J83,ECO:0000269|PubMed:12207896, ECO:0000269|PubMed:20580051,ECO:0000269|PubMed:22170153, ECO:0000269|PubMed:26812546}. May play an important role in the apoptotic process,possibly within the modified cytoskeleton. Its expression is arelatively late event in the apoptotic process, occurringdownstream of caspase activity. Plays a crucial role in IFN-gamma-induced autophagic cell death by interacting with FADD.{ECO:0000269|PubMed:15778222, ECO:0000269|PubMed:7796880}. (Microbial infection) May act as a proviral factor. Inassociation with ATG12, negatively regulates the innate antiviralimmune response by impairing the type I IFN production pathwayupon vesicular stomatitis virus (VSV) infection (PubMed:17709747).Required for the translation of incoming hepatitis C virus (HCV)RNA and, thereby, for initiation of HCV replication, but notrequired once infection is established (PubMed:19666601).{ECO:0000269|PubMed:17709747, ECO:0000269|PubMed:19666601}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for ATG5_EPHA7 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| >In-frame_ATG5_ENST00000369076_chr6_106756239_-_EPHA7_ENST00000369303_chr6_93982140_-_636aa MTDDKDVLRDVWFGRIPTCFTLYQDEITEREAEPYYLLLPRVSYLTLVTDKVKKHFQKVMRQEDISEIWFEYEGTPLKCSLASEWSNEGE STAAECRAFLAGTRASQWSHHRIXNQVLRERSKGTDLLNSKNQVYFSLHXXSETRNSVCFPDSGFYCCWLWKLQSQTXCCYTRGSYRXNV XSYSCLQXTESCYYHCCGCCSWDHHFGVHGLWLHHWEKALWLXQSXPRRRXRALLSFXISRHQNLHXPXNLXGPKXSCPSIRQGARCLLY XNXACDWCRRIRXSLQWPFETSREKRCCSSHKNPESWLHRKTKERLFVXSKHHGAVXPPECCPFGRGCYKRETSHDSNRVHGKWSPRCIS QETXWAIYSHSVSRNAERNCCWNEIFGXYGICSQGPCSSQYSCQQQSRLXSVRFWPVPSYRGXSRSCLYNYWWKNSSKVDSTRSHPVPEI HISQXCMELWNSHVGSYVLWRKTLLGHVKSRCYKSNRRRLSFTSTHGLPSWPSPANVGLLAKGACXKAKIXTDSWNSRQNDSKPKXSENS PGNLXXANKPSSGSKHSXFHYLLFSWRMATSYXDGKIXRXFHGSWLQFPXISSQDDYXGCDEFRDHTGWSSKENHEQHSDYESTNATFTW |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| >In-frame_ATG5_ENST00000369076_chr6_106756239_-_EPHA7_ENST00000369303_chr6_93982140_-_1909nt ATGACAGATGACAAAGATGTGCTTCGAGATGTGTGGTTTGGACGAATTCCAACTTGTTTCACGCTATATCAGGATGAGATAACTGAAAGG GAAGCAGAACCATACTATTTGCTTTTGCCAAGAGTAAGTTATTTGACGTTGGTAACTGACAAAGTGAAAAAGCACTTTCAGAAGGTTATG AGACAAGAAGACATTAGTGAGATATGGTTTGAATATGAAGGCACACCACTGAAATGCTCCCTCGCAAGTGAGTGGAGTAATGAAGGAGAG AGTACTGCAGCGGAGTGTCGAGCTTTCCTGGCAGGAACCAGAGCATCCCAATGGAGTCATCACAGAATATGAAATCAAGTATTACGAGAA AGATCAAAGGGAACGGACCTACTCAACAGTAAAAACCAAGTCTACTTCAGCCTCCATTAATAATCTGAAACCAGGAACAGTGTATGTTTT CCAGATTCGGGCTTTTACTGCTGCTGGTTATGGAAATTACAGTCCCAGACTTGATGTTGCTACACTAGAGGAAGCTACAGGTAAAATGTT TGAAGCTACAGCTGTCTCCAGTGAACAGAATCCTGTTATTATCATTGCTGTGGTTGCTGTAGCTGGGACCATCATTTTGGTGTTCATGGT CTTTGGCTTCATCATTGGGAGAAGGCACTGTGGTTATAGCAAAGCTGACCAAGAAGGCGATGAAGAGCTTTACTTTCATTTTAAATTTCC AGGCACCAAAACCTACATTGACCCTGAAACCTATGAGGACCCAAATAGAGCTGTCCATCAATTCGCCAAGGAGCTAGATGCCTCCTGTAT TAAAATTGAGCGTGTGATTGGTGCAGGAGAATTCGGTGAAGTCTGCAGTGGCCGTTTGAAACTTCCAGGGAAAAGAGATGTTGCAGTAGC CATAAAAACCCTGAAAGTTGGTTACACAGAAAAACAAAGGAGAGACTTTTTGTGTGAAGCAAGCATCATGGGGCAGTTTGACCACCCGAA TGTTGTCCATTTGGAAGGGGTTGTTACAAGAGGGAAACCAGTCATGATAGTAATAGAGTTCATGGAAAATGGAGCCCTAGATGCATTTCT CAGGAAACATGATGGGCAATTTACAGTCATTCAGTTAGTAGGAATGCTGAGAGGAATTGCTGCTGGAATGAGATATTTGGCTGATATGGG ATATGTTCACAGGGACCTTGCAGCTCGCAATATTCTTGTCAACAGCAATCTCGTTTGTAAAGTGTCAGATTTTGGCCTGTCCCGAGTTAT AGAGGATGATCCAGAAGCTGTCTATACAACTACTGGTGGAAAAATTCCAGTAAGGTGGACAGCACCCGAAGCCATCCAGTACCGGAAATT CACATCAGCCAGTGATGTATGGAGCTATGGAATAGTCATGTGGGAAGTTATGTCTTATGGAGAAAGACCTTATTGGGACATGTCAAATCA AGATGTTATAAAAGCAATAGAAGAAGGTTATCGTTTACCAGCACCCATGGACTGCCCAGCTGGCCTTCACCAGCTAATGTTGGATTGTTG GCAAAAGGAGCGTGCTGAAAGGCCAAAATTTGAACAGATAGTTGGAATTCTAGACAAAATGATTCGAAACCCAAATAGTCTGAAAACTCC CCTGGGAACTTGTAGTAGGCCAATAAGCCCTCTTCTGGATCAAAACACTCCTGATTTCACTACCTTTTGTTCAGTTGGAGAATGGCTACA AGCTATTAAGATGGAAAGATATAAAGATAATTTCACGGCAGCTGGCTACAATTCCCTTGAATCAGTAGCCAGGATGACTATTGAGGATGT GATGAGTTTAGGGATCACACTGGTTGGTCATCAAAAGAAAATCATGAGCAGCATTCAGACTATGAGAGCACAAATGCTACATTTACATGG |
| * Fusion transcript sequences (Full-length transcript). |
| >In-frame_ATG5_ENST00000369076_chr6_106756239_-_EPHA7_ENST00000369303_chr6_93982140_-_5639nt CTGGACTTGTGGTGCGCTGCCAGGGCTCCGCAGCGTTGCCGGTTGTATTCGCTGGATACCAGAGGGCGGAAGTGCAGCAGGGTTCAGCTC CGACCTCCGCGCCGGTGCTTTTTGCGGCTGCGCGGGCTTCCTGGAGTCCTGCTACCGCGTCCCCGCAGGACAGTGTGTCAGGCGGGCAGC TTGCCCCGCCGCCCCACCGGAGCGCGGAATCTGGGCGTCCCCACCAGTGCGGGGAGCCGGAAGGAGGAGCCATAGCTTGGAGTAGGTTTG GCTTTGGTTGAAATAAGAATTTAGCCTGTATGTACTGCTTTAACTCCTGGAAGAATGACAGATGACAAAGATGTGCTTCGAGATGTGTGG TTTGGACGAATTCCAACTTGTTTCACGCTATATCAGGATGAGATAACTGAAAGGGAAGCAGAACCATACTATTTGCTTTTGCCAAGAGTA AGTTATTTGACGTTGGTAACTGACAAAGTGAAAAAGCACTTTCAGAAGGTTATGAGACAAGAAGACATTAGTGAGATATGGTTTGAATAT GAAGGCACACCACTGAAATGCTCCCTCGCAAGTGAGTGGAGTAATGAAGGAGAGAGTACTGCAGCGGAGTGTCGAGCTTTCCTGGCAGGA ACCAGAGCATCCCAATGGAGTCATCACAGAATATGAAATCAAGTATTACGAGAAAGATCAAAGGGAACGGACCTACTCAACAGTAAAAAC CAAGTCTACTTCAGCCTCCATTAATAATCTGAAACCAGGAACAGTGTATGTTTTCCAGATTCGGGCTTTTACTGCTGCTGGTTATGGAAA TTACAGTCCCAGACTTGATGTTGCTACACTAGAGGAAGCTACAGGTAAAATGTTTGAAGCTACAGCTGTCTCCAGTGAACAGAATCCTGT TATTATCATTGCTGTGGTTGCTGTAGCTGGGACCATCATTTTGGTGTTCATGGTCTTTGGCTTCATCATTGGGAGAAGGCACTGTGGTTA TAGCAAAGCTGACCAAGAAGGCGATGAAGAGCTTTACTTTCATTTTAAATTTCCAGGCACCAAAACCTACATTGACCCTGAAACCTATGA GGACCCAAATAGAGCTGTCCATCAATTCGCCAAGGAGCTAGATGCCTCCTGTATTAAAATTGAGCGTGTGATTGGTGCAGGAGAATTCGG TGAAGTCTGCAGTGGCCGTTTGAAACTTCCAGGGAAAAGAGATGTTGCAGTAGCCATAAAAACCCTGAAAGTTGGTTACACAGAAAAACA AAGGAGAGACTTTTTGTGTGAAGCAAGCATCATGGGGCAGTTTGACCACCCGAATGTTGTCCATTTGGAAGGGGTTGTTACAAGAGGGAA ACCAGTCATGATAGTAATAGAGTTCATGGAAAATGGAGCCCTAGATGCATTTCTCAGGAAACATGATGGGCAATTTACAGTCATTCAGTT AGTAGGAATGCTGAGAGGAATTGCTGCTGGAATGAGATATTTGGCTGATATGGGATATGTTCACAGGGACCTTGCAGCTCGCAATATTCT TGTCAACAGCAATCTCGTTTGTAAAGTGTCAGATTTTGGCCTGTCCCGAGTTATAGAGGATGATCCAGAAGCTGTCTATACAACTACTGG TGGAAAAATTCCAGTAAGGTGGACAGCACCCGAAGCCATCCAGTACCGGAAATTCACATCAGCCAGTGATGTATGGAGCTATGGAATAGT CATGTGGGAAGTTATGTCTTATGGAGAAAGACCTTATTGGGACATGTCAAATCAAGATGTTATAAAAGCAATAGAAGAAGGTTATCGTTT ACCAGCACCCATGGACTGCCCAGCTGGCCTTCACCAGCTAATGTTGGATTGTTGGCAAAAGGAGCGTGCTGAAAGGCCAAAATTTGAACA GATAGTTGGAATTCTAGACAAAATGATTCGAAACCCAAATAGTCTGAAAACTCCCCTGGGAACTTGTAGTAGGCCAATAAGCCCTCTTCT GGATCAAAACACTCCTGATTTCACTACCTTTTGTTCAGTTGGAGAATGGCTACAAGCTATTAAGATGGAAAGATATAAAGATAATTTCAC GGCAGCTGGCTACAATTCCCTTGAATCAGTAGCCAGGATGACTATTGAGGATGTGATGAGTTTAGGGATCACACTGGTTGGTCATCAAAA GAAAATCATGAGCAGCATTCAGACTATGAGAGCACAAATGCTACATTTACATGGAACTGGCATTCAAGTGTGATATGCATTTCTCCCTTT TAAGGGAGATTACAGACTGCAAGAGAACAGTACTGGCCTTCAGTATATGCATAGAATGCTGCTAGAAGACAAGTGATGTCCTGGGTCCTT CCAACAGTGAAGAGAAGATTTAAGAAGCACCTATAGACTTGAACTCCTAAGTGCCACCAGAATATATAAAAAGGGAATTTAGGATCCACC ATCGGTGGCCAGGAAAATAGCAGTGACAATAAACAAAGTACTACCTGAAAAACATCCAAACACCTTGAGCTCTCTAACCTCCTTTTTGTC TTATAGACTTTTTAAAATGTACATAAAGAATTTAAGAAAGAATATATTTGTCAAATAAAATCATGATCTTATTGTTAAAATTAATGAAAT ATTTTCCTTAAATATGTGATTTCAGACTATTCCTTTTTAAAATCATTTGTGTTTATTCTTCATAAGGACTTTGTTTTAGAAAGCTGTTTA TAGCTTTGGACCTTTTTAGTGTTAAATCTGTAACATTACTACACTGGGTACCTTTGAAAGAATCTCAAATTTCAAAAGAAATAGCATGAT TGAAGATACATCTCTGTTAGAACATTGGTATCCTTTTTGTGCCATTTTATTCTGTTTAATCAGTGCTGTTTTGATATTGTTTGCTAATTG GCAGGTAGTCAAGAAAATGCAAGTTGCCAAGAGCTCTGATATTTTTTAAAAAGAATTTTTTTGTAAAGATCAGACAACACACTATCTTTT CAATGAAAAAAGCAATAATGATCCATACATACTATAAGGCACTTTTAACAGATTGTTTATAGAGTGATTTTACTAGAAAGAATTTAATAA ACTCGAAGTTTAGGTTTATGAGTATATAAACAAATGAGGCACTTCATCTGAAGAATGTTGGTGAAGGCAAGTCTCTGAAAGCAGAACTAT CCAGTGTTATCTAAAAATTAATCTGAGCACATCAAGATTTTTTCATTCTCGTGACATTAGGAAATTTAGGATAAATAGTTGACATATATT TTATATCCTCTTCTGTTGAATGCAGTCCAAACATGAAAGGAAATAATTGTTTTATATTATAACTCTGAAGCATGATAAAGGGGCAGTTCA CAATTTTCACCATTTAAACACAAATTTGCTGCACAGAATATCACCATTGCAGTTCAAAACAAAACAAAACAAAAAGTCTTTTGTTTGTGA ACACTGATGCAAGAAACTTGTTAAATGAAAGGACTCTTTACCCTAGAAGGAAGAGGTGAAGGATCTGGCTTGTTTTTAAAGCTTTATTTA TTAAACCATATTATTTGATTACTGTGTTAGAATTTCATAAGCAATAATTAAATGTGTCTTTATAGATATTGCAGGAATGTATACATATTG TGATTAATGCTTTCAAAACTTATGAAAATCATGAACTACCCCAGAATTGAACTGTTGTACTTCCAAAGAGAATTGGGCTGTTTATAATGA TTTTAATAGAGAAAGATCCCAGGGATCGGTCATAATTGGTCTTGTTTGATAATGTGGGCATCCACAAACAAACAAACAAATAACAGAAAC AAAATCTGTAAATGTTCCTTTGTAAAACTTGTAAATTTTATTTATACTGTCTTGTTTTGTACACACATTTCTCTGTAGTGGGCTCTGAAT ACATTGAAAATGCACTATATTTTTCTATTTTACTTGCAGAGCATCACAAAAGAACAGGTATTTTCAGTGCTACATAATGTGTTTTCCCAC ATTTAGGACCAAAGACGGCTATAGAAAAACTCAAATGGATTGCTTCCCAAACCCCTCCCCACCCTTTTTTTTTGGTTTTAAATCACTGTA CAGTGTTATTTGATATTTTAATTTATTTTTTGATTGACTAGAAAAATCATTTTAATTTCACTAAAATGTTTTTTGTCCCTAAGGAAAAGT AATCTGTAAAAATAATTTTAATTAGCATAATACAGTCACCTAGACACTTCCATTTGTAATCTTTGTAATAGACTGTAAATATATTTTTGG AACTATAACACAATGTGCTTGAGGGTTATTTTTCAGTGTCTGCAGTGTGTACAAGTGTTTATACTAAGTCCAGCACTTTACAATTCTAAT CAGTAGCATTGGCCTTTGTGAGAATGAGTGAAAGAGTTTGAGTGAGTGTTCTTAATTCCTTTTGGATTCTAGACTCACTAATAATGAAGT TCTTTTCTTGTTCATAGCTTAAGGTGCTTATTTTTTCTATTAAAATTAAATTAACAAAAGCCATTCTAGAAATAGAAGACATAGTATGGT ACATGCAAACGGTGTCTTTCCTGCTTTTTTCTAGCACTAGATTTATAGTTGAGTAGTCTTTCTTGAGTAGAAGGGCAGAATAAAAGTTTT TTTGAGTTTTTTTCAAAAATAAATTTTTCCTTCAGCAATATACCTCATCTGCCTTAAATTTTTTACAGCTCTTTACAGGGAAAGGGGAGA AGGGATGGGAAAGACACACAGCACAATAGGAAGTGTATGATTACATCACTATCTCGTTTGTAAGTTTCTTTTCCTAATCAACATTATGAT TTCGAAATACATGTATGTGAAACAAATATTAAGAGAAAAAGAATTAACATTGTAATGCTGATTGTAATACTCTCTTCCAGAAAGAGATGA GATGGTATAACGATAAGAATGTACAACTTGCACCTTGAAATCTTTTTTTTTAAATAAATTAGTGCTCAGGGGAGGAAAAGTAGAGAAAGT GAACGTCAAAAATAGAATTCCAAAATTATAAAAATGCAAAAGGAAATGGCCTCCTTGCTTTAATAGAGCCACCTTTTTTAGAACACTGTC CTCACACTTGACCTGTGTTTTGCATTCAGTACTGAAATAAAAGTAACTTGTTCTACATTTGAATCTAACATTTTCTCAGCAATTGATCTG GTCCTTGTTTACTAGAACTGGTGGTTTATGCTTGTCAGAGCACTATTAGTTGAATCATATTGTATACTTATGTAATCTACATTAGCTAGT ACTGTTTAGGACTATATTTTAATTGCTCTTCTTATCCGTGTTTTTAAGACAATTAAAATGGTGTGATTCACCTCTCTTTTTTATTTAGGT AATGCTGATATTCTCCCTTTTGTTTCTTGAGTAGCCTAGAACTATGCTACTCACTGATGTGCATGTTCAAATAAATTACTGATGTGTATT TTTTTGCTATATGTGGAGAAATCATGGGGAACTCGGGGCGAGATGTGCTTTTCGTTGGTTGAATTTGTCCCTCCTTGCCTAAGAAATACT ACAGGGGTCATCCTTTTATAAGGACAAACTGCTTTTGAACAGTGTCTTCAATGTATCAAGCACAAATAACTCTTTCTTCAACATGAATCA |
Top |
FusionGenePPI for ATG5_EPHA7 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| ATG5 | ATG12, IMPDH2, ATG16L1, ATG3, TECPR1, TKT, MAP1LC3B, MAP1LC3C, SIRT1, ELAVL1, TAB2, TAB3, WDFY3, HTT, CAV1, EXOC4, RB1CC1, FADD, WIPI2, MEOX2, VCP, KEAP1, CCHCR1, TEKT4, CAPN1, CAPN2, BCL2L1, XPO1, BCL10, SQSTM1, CALCOCO2, OPTN, BSN, IKBIP | EPHA7 | EFNA2, EFNA3, EFNA5, MLLT4, MAP1LC3A, GNB1, ZNF267, HLA-DPA1, CACNG2, TMEM231, TMEM30A, PICK1, UBR2, HERC2, TMEM216, EPHA10, MBLAC2, EPHA3, TMPRSS11B, BCAM, TMEM30B, TMX1, NID2, SMOC1, MICA, RPL23, EPHA4, LRRIQ1, MRAP2, NPTX1, TUBA4A, HSPA5, BORA, MANSC1, AGAP1, EMC1, IL17RC, IL17RB, OAF, IARS2, RAET1E, WNT5A, PC, DUSP18, DUSP26, STYX, MTMR14 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for ATG5_EPHA7 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for ATG5_EPHA7 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | ATG5 | C0002871 | Anemia | 1 | CTD_human |
| Hgene | ATG5 | C0019209 | Hepatomegaly | 1 | CTD_human |
| Hgene | ATG5 | C0023380 | Lethargy | 1 | CTD_human |
| Hgene | ATG5 | C0024312 | Lymphopenia | 1 | CTD_human |
| Hgene | ATG5 | C0027540 | Necrosis | 1 | CTD_human |
| Hgene | ATG5 | C1262477 | Weight decreased | 1 | CTD_human |
| Hgene | ATG5 | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
| Tgene | EPHA7 | C0149925 | Small cell carcinoma of lung | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|